Shanna Fuld

About the Author Shanna Fuld

Shanna J. Fuld is a journalist specializing in finance. Born and raised in Queens, New York, she’s been avoiding dates with finance guys for years – only to find herself becoming one. The former NY1er worked as a videographer, assignment editor and writer for the beloved local news channel before joining the Smarter Analyst team.

Analyst Shares His Experience Touring Tesla’s (TSLA) Factory; Has it Changed the Way He Views the Stock?

Jeffries’ Philippe Houchois has met with Tesla’s (TSLA) management at the Fremont factory. The analyst called the tour of the plant “an interesting mix of …

Aphria (APHA) Stock Plummets After Damning Reports, but Analysts Remain Supportive

Canadian marijuana company Aphria (APHA) has sunk deeper in the red after reports are out detailing shady business deals with Latin American companies. Quintessential Capital …

Does Bausch Health (BHC) Stock Have a Clean and Bright Future? Not According to This Analyst

J.P Morgan’s Chris Schott recently met with Bausch Health (BHC) management to talk about the future of the pharmaceutical company.

Get Ready for Square (SQ) Stock to Move Higher: Top Analyst

Stifel’s top analyst Scott Devitt predicts Square (SQ) will deliver solid results for the fourth quarter and then bring the momentum into 2019 as well. …

Qualcomm (QCOM) Stock: The Bulls Are Getting Nervous

Qualcomm’s (QCOM) stock continues to be in pain as investors are pulling out of technology stocks, especially semiconductors as fears of an oversupply …

Conatus Pharmaceuticals (CNAT) Stock Crashes After Trial Data Misses the Mark

Conatus Pharmaceuticals Inc. (CNAT) stock fell over 50% today amid disappointing results for the company’s 2b ENCORE-PH clinical trial in NASH cirrhosis.

MiMedx (MDXG) Stock Plunges on Back of Mass Layoff

MiMedx (MDXG) stock is collapsing, down nearly 61%, after announcing an organizational realignment program – or what the laymen call a mass firing. …

Analyst Sees Compelling Opportunity in Therapeutics MD (TXMD) Stock As Women’s Meds Grow in Popularity

Cantor’s analyst Louise Chen assumes coverage on pharmaceutical company TherapeuticsMD (TXMD) with an Overweight rating and price target of $27, showing an upside …

Top Analyst Drops Rating on Facebook (FB) Stock; Here’s Why

Stifel’s top analyst Scott Devitt is calling out Facebook (FB) for being “unstable.” The analyst suggests Facebook’s management team has created a slew of …

Be Patient With Alibaba (BABA) Stock And You Might Be Handsomely Rewarded

If patience is not your virtue, Alibaba (BABA) might be trying. Gainsboro Capital (GC) blogger says the e-commerce company continues to see its …